We are proud to share that Rockfish Bio, an associated member of the Austrian Cluster for Tissue Regeneration, has been awarded the S&B Award 2025 by the Rudolf Sallinger Fund. The spin-off company, founded by Cluster members Ingo Lämmermann and Johannes Grillari, emerged from research at BOKU University and the Medical University of Vienna.
Rockfish Bio impressed the jury with a new class of senolytic drug candidates that specifically eliminate senescent cells, aged, dysfunctional cells that accumulate in tissues and contribute to chronic and age-related diseases. By targeting a unique metabolic signature of these cells, the compounds remove harmful cells while sparing healthy ones.
Preclinical data demonstrate promising results: extended lifespan and healthspan, and restored neuromuscular function, underscoring the potential of these therapies in promoting healthy aging.
“We are honored to receive the S&B Award. This recognition is a great motivation and validation of our mission to develop effective therapies against aging-related diseases,” said Ingo Lämmermann, CSO/COO of Rockfish Bio.
The company was co-founded by Ingo Lämmermann and Johannes Grillari (BOKU and LBI Trauma), together with Otto Kanzler and Thomas Streimelweger. The project builds on pioneering senescence research by the teams of Johannes Grillari and Florian Gruber (MedUni Vienna).
